Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes-Reference-Cited by-同舟云学术

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

Published:2013-10-10 Issue:15 Volume:122 Page:2539-2549
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Dubovsky Jason A.¹,Beckwith Kyle A.¹²,Natarajan Gayathri³,Woyach Jennifer A.¹,Jaglowski Samantha¹,Zhong Yiming¹,Hessler Joshua D.¹,Liu Ta-Ming¹,Chang Betty Y.⁴,Larkin Karilyn M.¹,Stefanovski Matthew R.¹,Chappell Danielle L.¹,Frissora Frank W.¹,Smith Lisa L.¹,Smucker Kelly A.¹,Flynn Joseph M.¹,Jones Jeffrey A.¹,Andritsos Leslie A.¹,Maddocks Kami¹,Lehman Amy M.⁵,Furman Richard⁶,Sharman Jeff⁷,Mishra Anjali¹,Caligiuri Michael A.¹,Satoskar Abhay R.⁸,Buggy Joseph J.⁴,Muthusamy Natarajan¹,Johnson Amy J.¹⁹,Byrd John C.¹⁹

Affiliation:

1. Department of Internal Medicine, Division of Hematology,

2. Medical Scientist Training Program, and

3. Department of Microbiology, The Ohio State University, Columbus, OH;

4. Pharmacyclics, Inc., Sunnyvale, CA;

5. Center for Biostatistics, The Ohio State University, Columbus, OH;

6. Department of Medicine, Division of Hematology-Oncology, Weill Cornell Medical College, New York, NY;

7. Willamette Valley Cancer Institute/US Oncology, Springfield, OR; and

8. Department of Pathology, and

9. Division of Medicinal Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH

Abstract

Key Points Ibrutinib is the first clinically viable irreversible ITK inhibitor. Ibrutinib inhibits the formation of Th2 but not Th1 immunity.